AYTU BioScience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aytu BioScience, Inc. (AYTU) on December 8, 2020. The filing reports a material modification to the rights of security holders regarding a 1-for-10 reverse stock split approved by the Board of Directors and previously ratified by stockholders on April 23, 2020.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only quantitative data provided relates to capital structure:
- Post-Split Share Count: Approximately 12,949,570 shares of common stock issued and outstanding immediately following the split.
- Stock Symbol: AYTU (trading on the Nasdaq Capital Market).
- New CUSIP: 054754874 (effective December 9, 2020).
Material Changes
The primary material change is the implementation of a 1-for-10 reverse stock split effective at 8:00 a.m. Eastern Time on December 8, 2020. Key details include:
- Every 10 shares of issued and outstanding common stock were combined into one share.
- No fractional shares were issued; holdings were rounded up to the next whole number.
- Outstanding stock options and warrants were proportionally adjusted.
- Trading on a split-adjusted basis commenced on December 9, 2020.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the mechanics of the stock split. The document notes that the reverse split does not modify the rights or preferences of the common stock. Stockholders holding shares through brokers or nominees had their positions automatically adjusted without requiring further action.
Investor Verification Checklist
- Verify the adjusted share count in brokerage accounts reflects the 1-for-10 ratio and rounding up of fractional shares.
- Confirm the new CUSIP number (054754874) is associated with the holdings.
- Review the adjusted strike prices and share quantities for any outstanding options or warrants.
- Check subsequent filings for the impact of the reduced share count on per-share metrics and compliance with Nasdaq listing standards.